CD8+ cytolytic T lymphocytes and the skin

Experimental Dermatology

Volumn 7, Issue 4, 1998, Pages 121-131

  De Panfilis, G ^a  

^a SPEDALI CIVILI   (Italy)

Author keywords

Anti tumor cytolytic immune responses; Atopic dermatitis; CD11b; CD28; CD8+; CD8+ cytolytic T lymphocytes; CD8+ suppressor cells; Cytotoxic cells; Immunodermatology; Immunotherapy; Lichen planus; Psoriasis; SALT; SIS; T lymphocytes; Tc1; Tc2

Indexed keywords

CELLULAR IMMUNITY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOPHENOTYPING; LICHEN PLANUS; PATHOPHYSIOLOGY; PSORIASIS; REVIEW; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN INFLAMMATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0031679521     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0625.1998.tb00312.x     Document Type: Review

References (98)

1. Streilein J, Lymphocyte traffic, T-cell malignancies and the skin. J Invest Dermatol 1978: 71: 167-171.
2. Bos J, Zonneveid I, Das P, Krieg S, Van der Loos C, Kapsenberg M. The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J Invest Dermatol 1987: 88: 569-573.
3. Spetz A L, Strominger J, Groh-Spies V. T cell subsets in normal human epidermis. Am J Pathol 1996: 149: 665-674.
4. Streilein J. Skin-associated lymphoid tissue (SALT): origins and functions. J Invest Dermatol 1983: 80: 12S-16S.
5. Bos J D, Kapsenberg M L. The skin immune system. Immunol Today 1986: 7: 235-240.
6. Ledbetter J A. Evans R L, Lipinski M, Cunningham-Rundles L, Good R A, Herzenberg L A. Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man. J Exp Med 1981: 153: 310-318.
7. Mosmann T R, Cherwinski H, Bond M W, Giedlin M A, Coffman R L. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secretory proteins. J Immunol 1986: 136: 279-285.
8. Del Prete G F, De Carli M, Mastromauro C, Macchia D, Biagiotti R, Ricci M. Purified protein derivative of Mycobacterium tuberculosis and excretory/secretory antigen(s) of Toxocara canis expand in vitro human T cell with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991: 88: 346-350.
9. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997: 18: 263-266.
10. + T cells and clones activated in vivo and in vitro. Immunol Rev 1991: 123: 85-92.
11. Seder R A, Boulay J L, Finkelman F D et al. CD8 T cells can be primed in virro to produce IL-4. J Immunol 1992: 148: 1652-1658.
12. Croft M, Carter L, Swain S L, Dutton R W. Generation of polarized antigen-specific CDS effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994: 180: 1715-1728.
13. Salgame P, Abrams J S, Clayberger C et al. Differing lymphokine profiles of functional subsets of human CD4 and CDS T cell clones. Science 1991: 11: 279-282.
14. Evans R L, Lazarus H, Penta A C, Schlossman S F. Two functionally distinct subpopulations of human T cells that collaborate in the generation of cytotoxic cells responsible for cell-mediated lympholysis. J Immunol 1978: 120: 1423-1428.
15. + T cell. Immunol Today 1994: 15: 107-112.
16. Damle N K, Hansen J A, Good R A, Gupta S. Monoclonal antibody analysis of human T lymphocyte subpopulations exhibiting autologous mixed lymphocyte reactions. Proc Natl Acad Sci (USA) 1981: 78: 5096-5098.
17. Damle N K, Mohagheghpour N, Hansen J A, Engleman E G. Alloantigen-specific cytotoxic and suppressor T lymphocytes are derived from phenotypically distinct precursors. J Immunol 1983: 131: 2296-2300.
18. Azuma M, Cayabyab M, Buck D, Phillips J H, Lanier L L. CD28 interaction with B7 co-stimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 1992: 175: 353-360.
19. + cells that suppresses T cell proliferative responses. J Immunol 1983: 131: 2757-2761.
20. + cells that suppresses B cell differentiation. J Immunol 1984: 133: 2461-2469.
21. Yamada H, Martin P J, Braun M P, Beatty P G, Sadamoto K, Hansen J A. Monoclonal antibody 9.3 and anti-CD11 antibodies define reciprocal subsets of lymphocytes. Eur J Immunol 1985: 15: 1164-1168.
22. - T lymphocytes. Antigenic and functional properties. J Immunol 1993: 150: 1147-1154.
23. De Panfilis G. Do T "suppressor" cells exist? Int J Immunopathol Pharmacol 1997: 1: 107-109.
24. Sansoni P, Rowden G, Manara G C, Ferrari C, De Panfilis G. S-100-positive T cells are largely restricted to a CD8-positive, 9.3-negative subset. Virchows Arch B 1987: 53: 301-307.
25. + human peripheral blood T lymphocytes coexpresses the S-100 protein. Clin Exp Immunol 1988: 72: 357-361.
26. De Panfilis G, Rowden G, Manara G C, Ferrari C, Torresani C, Sansoni P. The S-100β protein in normal human peripheral blood is uniquely present within a discrete suppressor-T-cell compartment. Cell Immunol 1988: 114: 398-404.
27. - subpopulation. J Invest Dermatol: 1997: 109: 441.
28. Lum L G, Orcutt-Thordarson N, Seigneuret M C, Hansen J A. In vitro regulation of immunoglobulin synthesis by T-cell subpopulations defined by a new human T-cell antigen (9.3). Cell Immunol 1982: 72: 122-128.
29. Takayama H, Shinohara N, Kawasaki A et al. Antigen-specific directional target cell lysis by perforin-negative T lymphocyte clones. Int Immunol 1991: 3: 1149-1154.
30. Shinohara N, Huang Y Y, Muroyama A. Specific suppression of antibody responses by soluble protein-specific, class II-restricted cytolytic T lymphocyte clones. Eur J Immunol 1991: 21: 23-30.
31. Takayama H, Kojima H, Shinohara N. Cytotoxic T lymphocytes: the newly identified Fas (CD95)-mediated killing mechanism and a novel aspect of their biological functions. Adv Immunol 1995: 60: 289-321.
32. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996: 80: 225-235.
33. Mosmann T R, Sad S. The expanding universe of T-cell subsets. Th1, Th2 and more. Immunol Today 1996: 17: 138-146.
34. Carter L L, Duttun R W. Relative perform- and Fas-mediated lysis in T1 and T2 CD8 effector populations. J Immunol 1995: 155: 1028-1031.
35. Henkart P A. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1994: 1: 343-349.
36. Kojima H, Shinohara N, Hanaoka S et al. Two distinct pathways of specific killing revealed by perform mutant cytotoxic T lymphocytes. Immunity 1994: 1: 357-362.
37. + T cells secreting Th1 or Th2 cytokines. Immunity 1995: 2: 271-279.
38. + cells. Immunology 1993: 78: 226-236.
39. + T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993: 178: 889-895.
40. + T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med 1994: 180: 489-495.
41. Le Gros G, Erard F. Noncytotoxic, IL-4, IL-5, IL-10 producing CD8 T cells, their activation and effector functions. Curr Opin Immunol 1994: 6: 453-460.
42. + T cell clones can provide B cell help. J Immunol 1995: 154: 3118-3127.
43. + T cells. Immunol Rev 1991: 123: 209-216.
44. Kagi D, Ledermann B, Burki K et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994: 369: 31-37.
45. Kagi D, Ledermann B, Burki K, Zinkernagel R M. Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunopathological protection and pathogenesis in vivo. Ann Rev Immunol 1996: 14: 207-232.
46. De Panfilis G, Manara G, Ferrari C, Manfredi G, Allegra F. Imbalance in phenotypic expression of T cell subpopulations during different evolutional stages of lichen planus lesions. Acta Derm Venereol (Stockh) 1983: 63: 369-375.
47. + suppressor lymphocyte subsets within cutaneous infiltrates. Arch Dermatol 1989: 125: 844-845.
48. Norris D A, Travers J B, Leung D Y M. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 1997: 109: 1-4.
49. De Panfilis G, Manara G C, Ferrari C, Torresani C, Zucchi A, Devoto R M. Further characterization of the "incipient lesion of chronic stationary type psoriasis vulgaris in exacerbation". Acta Derm Venereol (Stockh) 1989: Suppl. 146: 26-30.
50. De Panfilis G, Manara G C, Ferrari C, Manfredi G, Brigati C, Allegra F. Cell subpopulations in psoriasis. Acta Derm Venereol (Stockh) 1984: Suppl. 113: 12-16.
51. + T cells in psoriatic lesions preferentially use T-cell receptor Vβ3 and/ or Vβ 13.1 genes. Proc Natl Acad Sci (USA) 1994: 91: 9282-9286.
52. Valdimarsson H, Baker B S, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995: 16: 145-149.
53. De Panfilis G, Manara G C, Allegra F. Remarks on early versus late lichen planus. Arch Dermatol Res 1981: 270: 163-166.
54. De Panfilis G, Rowden G. Quantitative studies on nonlymphoid mononuclear cell subpopulations in cutaneous infiltrates. I. Stage-related changes of dendritic nonlymphoid mononuclear cells. Langerhans cells, and macrophages in lichen planus lesions. Am J Dermatopathol 1986: 8: 44-52.
55. De Panfilis G. A quantitative labelled antibody study of the evolving patterns of T cell subsets in lichen planus. In: MacDonald D M, ed. Immunodermatology. Kent: Butterworths, 1984: 163-166.
56. De Panfilis G, Rowden G. The possibility of distinguishing a subset of antigen-presenting cells from macrophages by means of anti S-100 protein sera. Dermal infiltrate of lichen planus as a model. Scand J Immunol 1985: 21: 485-488.
57. De Panfilis G. The pathogenesis of lichen planus. Am J Dermatopathol 1987: 9: 362-363.
58. Ragaz A, Ackerman A B. Evolution, maturation, and regression of lesions of lichen planus. Am J Dermatopathol 1981: 3: 5-25.
59. Morhenn V B. The etiology of lichen planus: a hypothesis. Am J Dermatopathol 1986: 8: 154-156.
60. Giannotti B, De Panfilis G, Manara G C, Allegra F. Macrophage-T-lymphocyte interaction in lichen planus. An electron microscopic and immunocytochemical study. Arch Dermatol Res 1983: 275: 35-40.
61. Medenica M, Lorincz A. Lichen planus: an ultrastructural study. Acta Derm Venereol (Stockh) 1977: 57: 55-62.
62. Weedon D. Apoptosis in lichen planus. Clin Exp Dermatol 1980: 5: 425-429.
63. De Panfilis G, Manara G C, Sansoni P, Allegra F. T-cell infiltrate in lichen planus. Demonstration of activated lymphocytes using monoclonal antibodies. J Cutan Pathol 1983: 10: 52-58.
64. Tjernlund U M, Ia-like antigens in lichen planus. Acta Derm Venereol (Stockh) 1980: 60: 309-314.
65. Thomas J A, Janossy G, Graham-Brown R A C, Kung P C, Goldstein G. The relationship between T lymphocyte subsets and Ia-like antigen positive nonlymphoid cells in early stages of cutaneous T cell lymphoma. J Invest Dermatol 1982: 78: 169-176.
66. Reinherz E L, Kung P C, Goldstein G, Levery R H, Schlossman S F. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci USA 1980: 77: 1588-1592.
67. Holden C A, Morgan E W, MacDonald D M. The cell population in the cutaneous infiltrate of mycosis fungoides: in situ studies using monoclonal antisera. Br J Dermatol 1982: 106: 385-392.
68. Bhan A K, Harrist T J, Murphy G F, Mihm M C Jr. T cell subsets and Langerhans cells in lichen planus: in situ characterization using monoclonal antibodies. Br J Dermatol 1981: 105: 617-622.
69. Romagnani S. Regulation of the development of type 2 T-helper cells in allergy. Curr Opin Immunol 1994: 6: 838-846.
70. Bos J D. Immunology of atopic dermatitis. Int J Immunopathol Pharmacol 1997: 10: 91.
71. Leung D Y M. Pathogenesis and clinical aspects of atopic dermatitis. Int J Immunopathol Pharmacol 1997: 10: 119-122.
72. Giannetti A, Pastore S, Girolomoni G. Immunologic aspects of atopic dermatitis. Int J Immunopathol Pharmacol 1997: 10: 123-125.
73. Klubal R, Osterhoff B, Wang B, Kinet J P, Maurer D. Stingl G. The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients. J Invest Dermatol 1997: 108: 336-342.
74. Jung T, Lack G, Schauer U et al. Decreased frequency of interferon-γ- and interleukin-2-producing cells in patients with atopic diseases measured at the single cell level. J Allergy Clin Immunol 1995: 96: 515-527.
75. + cells in patients with atopic dermatitis. J All Clin Immunol 1997: 99: 673-682.
76. Lonati A, Seidenari S, Licenziati S et al. The Th1 and Tc1 subsets are both involved in the decrease of the population of lymphocytes producing IFN-γ in atopic dermatitis. Submitted for publication.
77. + lymphocytes of patients with AIDS synthesize increased amounts of interferon-γ. J AIDS Human Retrovirology 1995: 10: 462-470.
78. Grabbe S, Bruvers S, Gallo R L, Knisely T L, Nazareno R, Granstein R D. Tumor antigen presentation by murine epidermal cells. J Immunol 1991: 146: 3656-3661.
79. Cohen P J, Cohen P A, Rosenberg S A, Katz S I, Mulé J J. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Immunol 1994: 24: 315-319.
80. Romani N, Schuler G. The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system. Springer Semin Immunopathol 1992: 13: 265-279.
81. Goldberg A L, Rock K L. Proteolysis, proteasomes and antigen presentation. Nature 1992: 357: 375-379.
82. Barber L D, Parham P. The essence of epitopes. J Exp Med 1994: 180: 1191-1194.
83. Schneeberger A, Koszik F, Stingl G. Immunologic host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J Invest Dermatol 1995: 105: 110S-116S.
84. Aichele P, Brduscha-Riem K, Zinkernagel R M, Hengartner H, Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995: 182: 261-266.
85. Austyn J M. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 1996: 183: 1287-1292.
86. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995: 182: 255-260.
87. Celluzzi C M, Mayordomo J I, Storkus W J, Lotze M T, Falo L D Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996: 183: 282-287.
88. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996: 156: 2918-2926.
89. Zitvogel L, Mayordomo J I, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996: 183: 87-97.
90. Paglia P, Chiodoni C, Rodolfo M, Colombo M P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996: 183: 317-322.
91. Condon C, Watkins S C, Celluzzi C M, Thompson K, Falo L D Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996: 10: 1122-1128.
92. Celluzzi C M, Falo L D Jr. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J Invest Dermatol 1997: 108: 716-720.
93. Yang N S, Sun W H. Gene gun and other non-viral approaches for cancer gene therapy. Nat Med 1995: 1: 481-483.
94. Rock K L, Rothstein L, Gamble S, Fleischacker C. Characterization of antigen-presenting cells that present exogenous antigens in association with class I molecules. J Immunol 1993: 150: 438-446.
95. Imaeda S. The evolution of anti-tumor immunotherapy. J Invest Dermatol 1997: 108: 695-697.
96. Rothe M, Wong S C, Henzel W J, Goeddel D V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994: 78: 681-690.
97. O'Keefe E J. A new role for Langerhans cells: induction of immunity mediated by cytotoxic T lymphocytes. J Invest Dermatol 1997: 108: 693.
98. Seliger B, Maeurer M J, Ferrone S. TAP off - tumors on. Immunol Today 1997: 18: 292-299.